Gold Falls Amid Trump's Reversal on European Tariffs

Bausch Health Companies Inc. reported a 10% drop in stock price following the failure of its Phase 3 program evaluating rifaximin to delay the first episode of hepatic encephalopathy in patients with cirrhosis. The failure of the program means that there is no successor to the blockbuster drug Xifaxan, which is a key revenue driver for the company.